Lipoprotein apheresis.
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.
Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA. Electronic address: pmoriart@kumc.edu.
Patrick M
PM
Moriarty
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Linda
L
Hemphill
D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D001781:Blood Component Removal / Q000379:methods*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications / Q000628:therapy*; D008074:Lipoproteins / Q000097:blood*
D008074:Lipoproteins
Atherosclerosis; CVD; Familial hypercholesterolemia; LDL-C; Lipoprotein apheresis; Lp(a)